Floatz logo

Cytokine-Induced Killer Cell

Non-Small Cell Lung Cancer

Affiliated Hospital to Academy of Military Medical SciencesCell therapyPhase 2Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
59/ 100

Competitive context

1206 Active assets in the Non-Small Cell Lung Cancer cohort.

Asset / SponsorPhaseRating
Necitumumab
Jonsson Comprehensive Cancer Center
Phase 3BBB
Zorifertinib
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3BBB
Glumetinib
Shanghai JMT-Bio Inc.
Phase 3BBB
Veliparib
AbbVie
Phase 3BBB
Zoledronate
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 4BBB

View all 50 →

Same molecule, other indications

Cytokine-Induced Killer Cell is also rated in:

Hepatocellular CarcinomaDormant
CCC
Indicative ·
54 / 100
View asset →
colon carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
B-cell non-Hodgkin lymphomaDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →